, virologically suppressed since 4.2 (2.2Á5.4) years; 53 patients switched from a tenofovir (TDF)-based regimens; ATV was associated with 3TC in 83% patients. No virological failures or discontinuations were observed; three patients had a single viral blip in the range 50Á250 copies/mL; CD4' increased from 610 (518Á829) (Table 1) significantly improved CD4', lymphocytes, hepatic profile, renal profile and ALP; these patients had also a modest but significant decrease in haemoglobin. Conclusions: Switch from an unboosted atazanavir-based regimen to ATV'3TC or FTC regimen was effective and safe in this small sample, supporting the hypothesis of a potential two-steps de-intensification (removal of ritonavir and removal of one NRTI) in patients on long-lasting virological suppression. 
